GlassScriptPhysician profile
Randall Emmett Morris
NPI 1346377710
$9,471.41
in general payments reported to CMS, 2019-2025
40 companies · $914 in 2025
The $914 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,460 · 2020: $945 · 2021: $1,860 · 2022: $1,781 · 2023: $899 · 2024: $1,613 · 2025: $914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,426.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,483.55 | 2019-2025 | |
| Amgen INC. | $896.96 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $846.84 | 2019-2024 | Xarelto |
| Medtronic, INC. | $772.41 | 2021-2025 | Onyx Frontier, Symplicity G3, Micra |
| Merck Sharp & Dohme LLC | $733.95 | 2021-2025 | Verquvo, Capvaxive |
| Abbott Laboratories | $650.60 | 2019-2025 | Cardiomems |
| Impulse Dynamics (USA) INC. | $411.69 | 2022-2024 | Optimizer |
| Astrazeneca Pharmaceuticals LP | $373.06 | 2019-2024 | Farxiga |
| Esperion Therapeutics, INC. | $350.97 | 2021-2024 | Nexletol, Nexlizet |
| Boston Scientific Corporation | $346.38 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Watchman Flx, Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $338.62 | 2019-2025 | Jardiance |
| Atricure, INC. | $266.24 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $257.61 | 2019-2025 | Camzyos, Eliquis |
| Kiniksa Pharmaceuticals International, Plc | $178.49 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $168.43 | 2019-2024 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.